Abstract:While brain imaging and cerebrospinal fluid (CSF) biomarkers have been used in the early detection and tracking of Alzheimer's disease (AD), their ability to predict subsequent clinical decline remains to be defined. In this study, we compared the ability of baseline PET amyloid-β (Aβ) and CSF measurements to predict subsequent cognitive decline in unimpaired Presenilin-1 (PSEN1) E280A mutation carriers from the Colombian autosomal dominant AD (ADAD) kindred, up to almost 25 years before the kindred's estimated median age of 44 at the onset of mild cognitive impairment. Thirty-seven cognitively unimpaired mutation carriers and non-carriers, aged 20-44 years, were recruited from the Alzheimer's Prevention Initiative (API) Colombia Registry. Baseline cerebral-to-cerebellar florbetapir PET standard-uptake-value ratios (SUVRs) and CSF Aβ1-42, total-tau and phospho-tau181 levels were related to 2-3 year subsequent decline on the API preclinical ADAD composite cognitive test score, previously found to be associated with preclinical progression. The mixed random effect model was used to estimate the relationship between baseline measures and subsequent cognitive decline in the mutation carriers. In an independent replication, 2-3 year decline on the composite cognitive test score distinguished between carriers and non-carriers (p=0.03). In the carrier group, baseline florbetapir SUVRs and CSF p-tau/Aβ1-42 ratios were associated with subsequent decline on the composite cognitive test score (p=0.008, 0.04, respectively). CSF Aβ1-42, total tau, and p-tau levels alone were not (p= 0.19, 0.43 and 0.88, respectively), even after adjusting for age. Florbetapir SUVRs were slightly but not significantly better than CSF p-tau/Aβ1-42 ratios (p=0.09), and better than CSF Aβ1-42, total tau, and p-tau levels (p= 0.04, 0.04, and 0.06, respectively) in predicting subsequent cognitive decline. Aβ PET and, to a lesser extent, CSF p-tau/Aβ1-42 measurements may provide prognostic indicators of AD-related cognitive decline in ADAD mutation carriers. Indeed, Aβ PET may be a better prognostic indicator than CSF Aβ and tau levels in the group of mutation carriers assessed up to 25 years before their estimated age at clinical onset. Research is needed to further clarify the prognostic value of these biomarkers in cognitively unimpaired persons at risk for autosomal dominant and late-onset AD.

P4‐269: Relationships Between Baseline Biomarkers and Subsequent Cognitive Decline in Cognitively Unimpaired PSEN1 E280A Mutation Carriers from the Colombian Kindred with Autosomal Dominant Alzheimer's Disease